Today: 29 April 2026
XRP price steadies near $2 after U.S. Senate crypto bill delay — what to watch next week
17 January 2026
2 mins read

XRP price steadies near $2 after U.S. Senate crypto bill delay — what to watch next week

New York, Jan 17, 2026, 12:57 EST — Market closed.

  • After slipping late last week, XRP climbed roughly 1% to $2.07 during weekend trading.
  • A delayed U.S. Senate session on a crypto market-structure bill kept regulatory issues front and center.
  • Ripple and LMAX announced a multi-year agreement featuring $150 million in financing from Ripple and expanded adoption of RLUSD for institutional trading.

XRP held steady near $2.07 on Saturday, barely moving as weekend trading slowed following U.S. lawmakers’ decision to put a key crypto bill on hold.

The token trades nonstop, but the real sentiment test likely awaits when Washington gets back to business. Despite a strong start to 2026 across much of crypto, traders are now fixated on “rules” headlines that could either fuel inflows or cut them off.

The focal point is the Digital Asset Market Clarity Act, aiming to clearly define which regulator oversees what. In a market driven by exchanges and trading platforms, jurisdiction is key—it influences listings, product marketing, and risk valuation.

XRP dropped roughly 1.3% on Friday, settling near $2.08. Bitcoin stayed close to $95,700, while ether slipped to about $3,316. The moves came as the Senate Banking Committee delayed a session on the bill, according to market reports.

Coinbase CEO Brian Armstrong said the exchange can’t support the draft legislation “in its current form,” highlighting concerns over stablecoin rewards — the incentive payments on dollar-pegged tokens meant to maintain a $1 value. “We’d rather have no bill than a bad bill,” Armstrong wrote. Meanwhile, Senate Banking Committee Chairman Tim Scott said parties remain “at the table working in good faith.” Summer Mersinger, CEO of the Blockchain Association, described the delay as “a healthy part of policymaking.” Reuters

The Banking Committee’s online calendar continues to show the Jan. 15 executive session on the Clarity Act as postponed, with no rescheduled date announced.

Ripple, best known for its link to XRP, took a fresh institutional angle this week. LMAX Group announced it will use Ripple USD (RLUSD) as core collateral across its institutional trading setup. The firm also revealed Ripple is backing its cross-asset growth with $150 million in financing. LMAX CEO David Mercer called the deal a “milestone,” while Ripple stablecoins chief Jack McDonald said institutions are “increasingly recognising” blockchain’s potential to modernise market structure. LMAX Group

It’s not a straightforward link to XRP demand, and traders are well aware of that. Still, stablecoins are the backbone of crypto’s infrastructure today, and shifts in how major players post collateral or settle trades can quickly impact liquidity — often outpacing developments in the token’s own roadmap.

The obvious risk is the bill dragging on or returning in a shape that pleases neither banks nor exchanges. If it stretches out, the market ends up stuck in the same unclear spot — which usually hits volumes first, then prices.

The calendar is set. Senate Agriculture Committee Chairman John Boozman announced the committee aims to release the legislative text by the end of business on Jan. 21, with a markup scheduled for Jan. 27 at 3 p.m.

Meanwhile, XRP traders await a new reset date from the Senate Banking Committee. They’re also eyeing any change in stance from Coinbase and other industry lobbyists on whether the Clarity Act, as it stands, is acceptable.

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:50 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Micron stock set for Tuesday test after $1.8 billion Taiwan fab deal
Previous Story

Micron stock set for Tuesday test after $1.8 billion Taiwan fab deal

IonQ, Rigetti and QUBT move: what’s driving quantum computing stocks into next week
Next Story

IonQ, Rigetti and QUBT move: what’s driving quantum computing stocks into next week

Go toTop